Hanson & Doremus Investment Management Sells 70,897 Shares of Pfizer Inc. $PFE

Hanson & Doremus Investment Management cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 54.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 58,337 shares of the biopharmaceutical company’s stock after selling 70,897 shares during the period. Hanson & Doremus Investment Management’s holdings in Pfizer were worth $1,638,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Brighton Jones LLC grew its holdings in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC increased its position in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares in the last quarter. United Bank raised its stake in Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after buying an additional 6,415 shares during the period. Sei Investments Co. lifted its holdings in Pfizer by 31.5% during the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock worth $63,889,000 after acquiring an additional 631,523 shares in the last quarter. Finally, HUB Investment Partners LLC lifted its holdings in Pfizer by 45.3% during the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after acquiring an additional 31,896 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Negative Sentiment: Pfizer reported that its experimental lung cancer treatment, sigvotatug vedotin, missed the main goal in a late-stage Phase 3 trial, a setback that raises questions about the drug’s commercial prospects and the strength of the company’s oncology pipeline. Article: Pfizer’s experimental drug misses main goal of lung cancer trial
• Negative Sentiment: Investors are also digesting leadership turnover after Pfizer said CFO Dave Denton will step down effective August 15, which adds near-term uncertainty around financial leadership. Article: Pfizer (PFE) CFO Dave Denton to Step Down Effective August 15
• Neutral Sentiment: Pfizer said it is not planning a major acquisition in the next couple of years and instead wants to use artificial intelligence to improve operations, signaling a focus on internal efficiency rather than M&A-driven growth. Article: Pfizer Isn’t Expecting to Make Any Big Acquisition in the Next Couple of Years, but It’s Planning to Do This Instead
• Neutral Sentiment: Broader commentary around Pfizer’s valuation, dividend appeal, and obesity-drug strategy may be supporting longer-term investor interest, but these pieces are not likely the main driver of the stock’s move today. Article: Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. CICC Research initiated coverage on Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price objective for the company. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research note on Tuesday, June 9th. Morgan Stanley upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Finally, Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average price target of $28.82.

Pfizer Stock Down 0.6%

Pfizer stock opened at $25.07 on Tuesday. The company has a market cap of $142.87 billion, a P/E ratio of 19.14 and a beta of 0.34. Pfizer Inc. has a 1-year low of $23.11 and a 1-year high of $28.75. The company has a fifty day simple moving average of $26.18 and a 200 day simple moving average of $26.33. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same quarter in the prior year, the company posted $0.92 earnings per share. Pfizer’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Shareholders of record on Friday, May 8th were paid a $0.43 dividend. The ex-dividend date was Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer’s dividend payout ratio is currently 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.